Compare ASIC & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIC | SVRA |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2025 | 2009 |
| Metric | ASIC | SVRA |
|---|---|---|
| Price | $24.36 | $4.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $28.40 | $11.06 |
| AVG Volume (30 Days) | 73.7K | ★ 2.8M |
| Earning Date | 10-21-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.44 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $424,339,000.00 | N/A |
| Revenue This Year | $24.89 | N/A |
| Revenue Next Year | $22.34 | $4,204.68 |
| P/E Ratio | $16.69 | ★ N/A |
| Revenue Growth | ★ 23.41 | N/A |
| 52 Week Low | $16.73 | $4.13 |
| 52 Week High | $29.00 | $7.01 |
| Indicator | ASIC | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 41.93 |
| Support Level | $23.36 | $4.23 |
| Resistance Level | $25.62 | $5.47 |
| Average True Range (ATR) | 0.84 | 0.30 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 62.35 | 14.20 |
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).